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Abstract 23 
Purpose: Enteric-coated sodium bicarbonate (NaHCO3) can attenuate gastrointestinal (GI) symptoms 24 
following acute bicarbonate loading, although the subsequent effects on exercise performance have not 25 
been investigated. The purpose of this study was to examine the effects of enteric-coated NaHCO3 26 
supplementation on high-intensity exercise performance and GI symptoms. Methods: Eleven trained 27 
male cyclists completed three 4 km time trials after consuming; a placebo or 0.3 g∙kg–1 body mass 28 
NaHCO3 in enteric-coated or gelatin capsules. Exercise trials were timed with individual peak blood 29 
bicarbonate ion concentration ([HCO3
–]). Blood acid-base balance was measured pre-ingestion, pre-30 
exercise and post-exercise, whereas GI symptoms were recorded pre-ingestion and immediately pre-31 
exercise. Results: Pre-exercise blood [HCO3−] and potential hydrogen (pH) were greater for both 32 
NaHCO3 conditions (P < 0.0005) when compared to placebo. Performance time was faster with enteric-33 
coated (−8.5 ± 9.6 s, P = 0.044) and gelatin (−9.6 ± 7.2 s, P = 0.004) NaHCO3 compared to placebo, 34 
with no significant difference between conditions (mean difference = 1.1 ± 5.3 s, P = 1.000). 35 
Physiological responses were similar between conditions, although blood lactate ion concentration was 36 
higher with gelatin NaHCO3 (2.4 ± 1.7 mmol∙L
–1, P = 0.003) compared with placebo. Furthermore, 37 
fewer participants experienced GI symptoms with enteric-coated (n = 3) compared to gelatin (n = 7) 38 
NaHCO3. Discussion: Acute enteric-coated NaHCO3 consumption mitigates GI symptoms at the onset 39 
of exercise and improves subsequent 4 km cycling TT performance. Athletes who experience GI side-40 
effects after acute bicarbonate loading may therefore benefit from enteric-coated NaHCO3 41 
supplementation prior to exercise performance. 42 
 43 
Keywords: Alkalosis ∙ Extracellular buffering ∙ Gastrointestinal symptoms ∙ High-intensity exercise  44 
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Abbreviations 45 
[Cl–]  Chloride ion concentration 46 
[H+]  Hydrogen ion concentration 47 
[HCO3
–] Bicarbonate ion concentration 48 
[K+]  Potassium ion concentration 49 
[La–]  Lactate ion concentration 50 
[Na+]  Sodium ion concentration 51 
AU  Arbitrary units 52 
CI  Confidence intervals 53 
g  Hedge’s g 54 
GI  Gastrointestinal 55 
H+  Hydrogen ion 56 
NaHCO3 Sodium bicarbonate 57 
pH  Potential hydrogen 58 
ROF  Rating of perceived fatigue 59 
RPE  Rating of perceived exertion 60 
RPE-L  Localised rating of perceived exertion 61 
SD  Standard deviation  62 
TT  Time trial 63 
V̇O2peak  Peak oxygen uptake 64 
η2  Eta-squared  65 
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Introduction 66 
High-intensity exercise bouts are impaired by peripheral fatigue (Thomas et al. 2015), typically as a 67 
result of disturbances to intramuscular homeostasis (Jones et al. 2008). Significant decreases in muscle 68 
and blood potential hydrogen (pH) have been reported (Hollidge-Horvat et al. 2000) as a result of the 69 
glycolytic contribution during high-intensity exercise (Baker et al. 2010; Gastin, 2001). While the 70 
mechanisms responsible for the decline in muscular force across the neuromuscular junction are 71 
equivocal (Fitts, 2016; Westerblad, 2016), reductions in muscle pH are associated with simultaneous 72 
declines in muscle excitability (Cairns & Lindinger, 2008), contractility (Spriet et al. 1985), glycolytic 73 
enzyme activity (MacLaren, 1989) and exercise performance (Raymer et al. 2004). Exercise training 74 
and nutritional strategies that offset these perturbations to acid-base balance have therefore received 75 
considerable attention. 76 
Inducing metabolic alkalosis prior to exercise, which can be achieved by oral ingestion of 77 
sodium bicarbonate (NaHCO3), has been shown to improve various performance measures (e.g. power, 78 
speed, performance time) during single-bouts of high-intensity exercise (Matson & Tran, 1993; Peart 79 
et al. 2012; Lancha Junior et al. 2015). Through increases in extracellular bicarbonate ion concentration 80 
([HCO3
–]), NaHCO3 supplementation can augment buffering capacity (Siegler et al. 2010) and strong 81 
ion handling (Raymer et al. 2004), both of which favour high-intensity exercise performance. Although 82 
0.2 to 0.4 g∙kg–1 body mass NaHCO3 is generally regarded as ergogenic during high-intensity exercise 83 
(McNaughton et al. 2016), gastrointestinal (GI) symptoms can be a problematic side-effect, with some 84 
individuals reporting severe symptoms (e.g. vomiting and diarrhoea) at the onset of exercise (Burke & 85 
Pyne, 2007; Kahle et al. 2013). While some studies have shown that NaHCO3 can improve exercise 86 
performance despite GI distress (Price & Simons, 2010), there is evidence to suggest that symptoms 87 
may compromise the performance-enhancing effects of supplementation (Cameron et al. 2010; 88 
Saunders et al. 2014; Deb et al. 2018). Furthermore, there is evidence to suggest that athletes may be 89 
deterred from supplementing with NaHCO3 due to the risk of GI symptoms during training and/or 90 
competition (Heibel et al. 2018). 91 
Novel ingestion strategies are being investigated to alleviate GI symptoms, such as the 92 
administration of NaHCO3 in gastro-resistant capsules (Hilton et al. 2019a). Through the application of 93 
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an enteric coating, which resists dissolution at a low pH (e.g. stomach), acid-sensitive ingredients such 94 
as NaHCO3 can bypass the stomach (Barbosa et al. 2017). Consequently, this reduces the neutralisation 95 
of gastric acid and minimises adverse side-effects (e.g. GI symptoms associated with elevated carbon 96 
dioxide tension in the GI tract. Indeed, delayed-release NaHCO3 has been shown to reduce the incidence 97 
and severity of GI symptoms compared with an aqueous solution, whilst increasing blood [HCO3
–] and 98 
pH to comparable levels. In a recent study, enteric-coated NaHCO3 was shown to attenuate GI 99 
symptoms beyond encapsulation in gelatin and delayed-release capsules, which may be more 100 
favourable for those who experience GI symptoms post-ingestion (Hilton et al. 2019b). Nevertheless, 101 
changes in blood [HCO3
–] and pH were lower with enteric-coated NaHCO3, potentially due to the 102 
absorption of bicarbonate across the intestinal mucosa (Turnberg et al. 1970) and less time available for 103 
absorption. Given that the degree of alkalosis can modulate the effects of NaHCO3 ingestion on exercise 104 
performance (Carr et al. 2011a), enteric-coated formulations may not favour performance 105 
improvements compared with alternative ingestion strategies. While enteric-coated NaHCO3 can reduce 106 
GI symptoms post-ingestion, no study to date has investigated the effects of supplementation on 107 
exercise performance. Therefore, it is unknown whether ingesting NaHCO3 in enteric-coated capsules 108 
alters the overall ergogenicity of supplementation. Furthermore, knowledge of the performance-109 
enhancing potential of enteric-coated NaHCO3 would help to elucidate the impact of GI symptoms and 110 
acid-base balance on exercise performance, as well as improve the practical recommendations for 111 
athletes. The aim of the present study, therefore, was to determine whether enteric-coated NaHCO3 112 
improves high-intensity exercise performance using an acute loading protocol. 113 
 114 
Methods 115 
Participants 116 
Eleven trained male cyclists (according to DePauw et al. 2013) were recruited for the study (mean ± 117 
SD: age, 32 ± 12 years; body mass, 81.5 ± 12.5 kg; height 1.8 ± 0.1 m; peak oxygen uptake [V̇O2peak], 118 
63.2 ± 4.9 mL∙kg–1∙min–1) based upon sample size estimation. Sample size was determined a priori and 119 
revealed that eleven participants were required to detect changes (~ 3 s; 1.3%) in performance time 120 
between conditions with high statistical power (α = 0.05; β = 0.20). The benchmark for change in 121 
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performance was chosen as it reflects the difference in performance time between podium and non-122 
podium positions for similar cycling events (Christensen et al. 2017). All participants undertook regular 123 
cycling (≥ 3 d∙week–1) for at least 5 h∙week–1 and were free of GI-related disorders. Exclusion criteria 124 
included those with hypertension, renal impairment or following a salt-restricted diet, and no 125 
participants were ingesting any nutritional supplements or medications at the time of the study. Ethical 126 
approval was obtained by the institutional research ethics committee and all participants gave written 127 
informed consent to take part in the study. 128 
 129 
Experimental design 130 
In a randomised, double-blind, and crossover design, participants attended the laboratory on six 131 
occasions, separated by at least 48 h and at the same time of day (0900 h). During the initial visit, 132 
participants completed a preliminary test to determine V̇O2max before familiarisation with the 4 km 133 
cycling time trial (TT). During the further two visits, individual responses to NaHCO3 ingestion (gelatin 134 
and enteric-coated) were established to determine subsequent ingestion timings. Throughout the next 135 
three visits, participants performed a maximal 4 km cycling TT under three different experimental 136 
conditions that were administered in a counterbalanced order. Experimental trials involved the 137 
consumption of 0.3 g∙kg–1 body mass of NaHCO3 in either enteric-coated or gelatin capsules, or a 138 
placebo containing cornflour prior to the 4 km TT. Participants were instructed to abstain from alcohol 139 
and caffeine consumption for 12 h, and strenuous exercise 24 h before each laboratory visit. Water 140 
intake was encouraged in the 24 h preceding experimental testing and participants were asked to arrive 141 
at the laboratory well-hydrated and after an overnight fast to minimise the confounding effects of food 142 
intake on gastric emptying rates (Davis et al., 1986). On arrival to the laboratory, pre-test instructions 143 
were confirmed verbally to limit confounding nutritional effects on exercise performance. Physiological 144 
(heart rate and blood lactate) and perceptual responses were recorded throughout the 4 km TT, whereas 145 
acid-base balance and GI symptoms were recorded immediately pre- and post-exercise. 146 
 147 
Preliminary testing 148 
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Participants undertook an incremental exercise test to volitional exhaustion on an electromagnetically-149 
braked cycle ergometer (Lode Excalibur Sport, Groningen, The Netherlands) which confirmed that 150 
V̇O2peak was > 55 mL∙kg–1∙min–1. The protocol involved a 5 min warm-up at 70 W and a self-selected 151 
cadence (70–120 rev∙min–1), after which the workload increased by 1 W every 2 s (30 W·min–1) until 152 
volitional exhaustion. Breath-by-breath gases were measured continuously throughout using a gas 153 
analyser (Oxycon Pro™, Jaeger, Germany) whereas heart rate (Polar®, Kempele, Finland) and whole-154 
body ratings of perceived exertion (RPE) were recorded each minute (Borg, 1973). The following 155 
criteria were used to confirm that V̇O2peak had been reached: (i) heart rate within 10 beats∙min–1 of age-156 
predicted maximum; (ii) respiratory exchange ratio > 1.10 arbitrary units (AU); (iii) RPE > 18/20 AU 157 
(Midgley et al. 2007). After a period of recovery (30 min), participants performed a 4 km cycling TT 158 
to familiarise themselves with the exercise protocol. 159 
Individual responses to the ingestion of enteric-coated and gelatin NaHCO3 were established to 160 
allow exercise to be scheduled with peak bicarbonate buffering capacity. This method accounts for the 161 
inter-individual variability in acid-base kinetics following NaHCO3 ingestion (Jones et al. 2016) and 162 
differences between ingestion forms (Hilton et al. 2019b). Semi-nude body mass was recorded (Bod 163 
Pod®, Cosmed, Rome, Italy) after bladder evacuation to determine the dose of NaHCO3. Participants 164 
then consumed 0.3 g·kg–1 body mass of NaHCO3 which was administered in either size 0 opaque 165 
enteric-coated (Bicarbi™, Nephcentric©, Arizona, USA), or gelatin capsules (Bulk Powders™, 166 
Colchester, UK). Enteric-coated capsules were pre-filled by the manufacturer, whereas gelatin capsules 167 
were manually filled by the researcher using a capsule filling device (Capsule Connection LLC, 168 
Arizona, USA). Given that each capsule contained 0.65 g of NaHCO3, supplements were administered 169 
to the nearest whole capsule. All supplements were checked for accuracy (Ohaus®, Fisher Scientific™, 170 
Pennsylvania, USA) prior to administration and were ingested with an equal volume (6 mL·kg–1 body 171 
mass) of water (Evian®, Danone, Paris, France) within 5 min of commencing ingestion. Fingertip 172 
capillary blood samples (95 μL) were drawn pre-ingestion and then every 20 min for 180 min post-173 
ingestion, with 10 min sampling from 80 to 140 min. Fingertip capillary blood samples were collected 174 
in heparin-coated glass capillary tubes (Radiometer Medical Ltd, Copenhagen, Denmark) using an 175 
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aseptic technique and analysed immediately (Radiometer ABL800 BASIC, Copenhagen, Denmark) for 176 
blood [HCO3
–] and pH. 177 
  178 
Experimental trials 179 
Upon arrival to the laboratory, participants sat resting for 20 min before a baseline (pre-ingestion) 180 
capillary blood sample was taken. Participants then ingested either 0.3 g·kg–1 body mass of NaHCO3 181 
administered in gelatin or enteric-coated capsules, or a placebo. Opaque gelatin capsules were also used 182 
in the placebo trials and an equal number of capsules (39 ± 13 capsules) were given to mask the 183 
experimental conditions. Pre-exercise acid-base balance was determined with a further blood sample, 184 
after the pre-determined time-to-reach peak blood [HCO3
–] had passed. All blood samples were 185 
analysed immediately for [HCO3
–] and pH, as well as sodium ([Na+]), potassium ([K+]) and chloride 186 
ion ([Cl–]) concentrations. 187 
 188 
Time trials 189 
Participants selected a preferred handlebar and saddle position which was then replicated for all other 190 
experimental trials. After a 5 min self-selected warm-up and 3 min rest, participants performed a 191 
maximal 4 km cycling TT on an electromagnetically-braked cycle ergometer (Velotron Pro®, 192 
RacerMate™, Seattle, USA) from a static start. Participants were instructed to complete the TT as fast 193 
as possible and were free to change gears throughout, although gear ratios were fixed. Visual feedback 194 
of cadence, gearing and distance travelled was provided on-screen, although participants were blinded 195 
from power output, speed and time elapsed. Strong verbal encouragement was given by the same 196 
individual at regular (0.5 km) intervals throughout and no water was provided during the TT. All TTs 197 
took place under standardised laboratory conditions (temperature 18-20 °C, humidity 45 ± 5%) and a 198 
fan was placed 5 m in front of the cycle ergometer to promote evaporative cooling. Participants 199 
undertook a 5 min cool-down at a self-selected workload immediately after completion of the TT. 200 
 201 
Physiological and perceptual measures 202 
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During each TT, blood lactate ion concentration ([La–]) was measured pre- and post-exercise, and every 203 
1 km throughout using a portable lactate monitor (Lactate Pro 2, Arkray, Japan). At the same time 204 
points, lower-limb ratings of perceived exertion (RPE-L) and RPE were recorded using a 6–20 scale 205 
(Borg, 1973), whereas perceived ratings of fatigue (ROF) were recorded on a 10-point Likert scale 206 
(Micklewright et al. 2017). Heart rate was measured pre- and post-exercise, and every 0.5 km 207 
throughout the TT (Polar®, Kempele, Finland). Symptoms of GI distress were recorded immediately 208 
pre-exercise using an adapted GI symptom questionnaire (Carr et al. 2011b) including nausea, 209 
flatulence, stomach cramping, belching, stomach ache, bowel urgency, diarrhoea, vomiting, and 210 
stomach bloating. Symptoms were self-measured on a 10 cm visual analogue scale where “0 = No 211 
symptom” and “10 = Severe symptom” (Miller et al. 2016). Symptom terminology was explained to 212 
participants before the experimental trials commenced to ensure consistency in the reporting of 213 
symptoms.  214 
 215 
Statistical analyses 216 
Data normality was assessed using the Shapiro–Wilk test and by visual inspection of the normality plots 217 
(Grafen & Hails, 2002). One-way analysis of variance (ANOVA) for repeated-measures were used to 218 
compare performance time and GI symptom scores. All performance (i.e. power), acid-base balance 219 
(i.e. blood [HCO3
–], pH, [Na+], [K+] and [Cl–]), physiological (i.e. blood [La–] and heart rate) and 220 
perceptual (i.e. RPE, RPE-L and ROF) variables were analysed using two-way (condition × time) 221 
ANOVA for repeated-measures. Where a significant main effect was revealed, Bonferroni-adjusted 222 
post-hoc paired comparisons were determined (Atkinson, 2002). Effect sizes were reported as eta-223 
squared (η2) for one- and two-way ANOVA, whereas Hedge’s g and 95% confidence intervals (CI) 224 
were calculated for paired comparisons (Lakens, 2013). Effects were discussed in relation to the 225 
relevant literature (Thompson, 2007) and described as small (η2 = 0.01; g = 0.2), medium (η2 = 0.06; g 226 
= 0.5), or large (η2 = 0.14; g = 0.8) as previously suggested (Cohen, 1988). Statistical significance was 227 
set at P < 0.05 and values for P of “0.000” given by the statistical package were corrected to “< 0.0005” 228 
(Kinnear & Gray, 1995). Descriptive data are presented as mean ± standard deviation (SD) throughout. 229 
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Data were analysed using the Statistical Package for the Social Sciences version 25 software (IBM®, 230 
Chicago, USA), whereas sample size was calculated using GPower® version 3.1.9.2 (Faul et al. 2007). 231 
 232 
Results 233 
Exercise performance 234 
There was a significant improvement in performance time (Fig. 1) in the NaHCO3 trials compared with 235 
the placebo (F2.0, 20.0 = 10.6, P = 0.001, η
2 = 0.52). Performance time was significantly faster with 236 
enteric-coated (mean difference = 8.5 s [−2.3%], P = 0.044, 95% CI [0.2, 16.9 s], g = 0.4) and gelatin 237 
(mean difference = 9.6 s [−2.6%], P = 0.004, 95% CI [3.4, 15.9 s], g = 0.5) NaHCO3 compared with 238 
the placebo, but there was no difference between enteric-coated and gelatin NaHCO3 (mean difference 239 
= −1.1 s, P = 1.00, 95% CI [–5.7, 3.5 s], g = 0.1). 240 
 241 
Fig. 1 Mean ± SD 4 km TT performance time following the ingestion of 0.3 g·kg–1 body mass NaHCO3 242 
in gelatin or enteric-coated capsules, or a placebo. Dotted lines denote individual performance times. 243 
✱Significant difference between gelatin NaHCO3 and placebo (P < 0.05). 
#Significant difference 244 
between enteric-coated NaHCO3 and placebo (P < 0.05) 245 
 246 
Acute bicarbonate loading had a significant effect on power output (F2.0, 20.0 = 8.8, P = 0.002, 247 
η2 = 0.10; Fig. 2), with higher values during the gelatin trial when compared with the placebo (mean 248 
difference = 24 W [+7.7%], P = 0.023, 95% CI [3, 45 W], g = 0.5). No further differences in power 249 
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output were shown between trials (P > 0.05). There was significant variation in power output across the 250 
TT (F1.4, 14.1 = 12.8, P = 0.002, η
2 = 0.34) with power output declining between 1 and 2 km (P = 0.001) 251 
before reaching a plateau (P = 0.123) at 3 km, followed by an increase towards 4 km (P = 0.026). Pacing 252 
strategies were similar between conditions (Fig. 2), with no significant condition × time interaction (F2.6, 253 
26.1 = 0.4, P = 0.746, η
2 = 0.01). No order effect on TT performance was shown given that neither 254 
performance time nor power output differed between the first to last trial (all P > 0.05). 255 
 256 
Fig. 2 Mean ± SD power output following the ingestion of 0.3 g·kg–1 body mass NaHCO3 in gelatin or 257 
enteric-coated capsules, or a placebo. ✱Significant difference between gelatin NaHCO3 and placebo (P 258 
< 0.05) 259 
 260 
Acid–base balance 261 
The time-to-reach individual peak blood [HCO3
−] was 110 ± 20 min (range 80-140 min) and 90 ± 20 262 
min (range 60-130 min) in the enteric-coated and gelatin conditions, respectively. Blood [HCO3
–] was 263 
significantly higher in the NaHCO3 conditions compared with the placebo (F2.0, 20.0 = 23.5, P <0.0005, 264 
η2 = 0.04, Fig. 3a), with no difference between enteric-coated and gelatin capsules (P = 1.0). Blood 265 
[HCO3
–] increased pre-exercise (P < 0.0005) followed by a decrease post-exercise (P < 0.0005), with a 266 
condition × time interaction (F4.0, 40.0 = 48.2, P < 0.0005, η
2 = 0.87). Pre-exercise blood [HCO3
–] was 267 
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significantly higher in the enteric-coated (3.8 ± 1.0 mmol∙L–1, P < 0.0005, 95% CI [3.0, 4.7 mmol∙L–1], 268 
g = 3.8) and gelatin (5.6 ± 1.5 mmol∙L–1, P < 0.0005, 95% CI [4.3, 6.3 mmol∙L–1], g = 4.3) conditions 269 
compared with the placebo. Furthermore, blood [HCO3
–] was significantly lower with enteric-coated 270 
compared with gelatin capsules pre-exercise (mean difference = 1.8 mmol∙L–1, P = 0.012, 95% CI [0.4, 271 
3.3 mmol∙L–1], g = 1.5). 272 
 273 
Fig. 3 Mean ± SD blood (a) [HCO3
–] (b) pH (c) [Na+] and (d) [K+] pre-ingestion, pre-exercise (post-274 
ingestion) and post-exercise. ✱Significant difference between gelatin NaHCO3 and placebo (P < 0.05). 275 
#Significant difference between enteric-coated NaHCO3 and placebo (P < 0.05). 
†Significant difference 276 
between gelatin and enteric-coated NaHCO3 (P < 0.05) 277 
 278 
Blood pH was significantly higher in the NaHCO3 conditions compared with the placebo (F2.0, 279 
20.0 = 14.6, P <0.0005, η
2 = 0.04, Fig. 3b), with no difference between enteric-coated and gelatin capsules 280 
(P = 1.0). Blood pH increased pre-exercise (P < 0.0005) followed by a decrease post-exercise (P < 281 
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0.0005), with a condition × time interaction (F2.0, 19.7 = 48.2, P = 0.001, η
2 = 0.03). Pre-exercise blood 282 
pH was significantly higher in the enteric-coated (0.038 ± 0.016 AU, P < 0.0005, 95% CI [0.024, 0.052 283 
AU]) and gelatin (0.074 ± 0.019 AU, P < 0.0005, 95% CI [0.058, 0.091 AU]) conditions compared with 284 
the placebo. Blood pH was also significantly lower with enteric-coated compared with gelatin capsules 285 
pre-exercise (mean difference = 0.037 AU, P = 0.001, 95% CI [0.018, 0.055 AU], g = 1.6). 286 
 287 
Electrolyte responses 288 
Acute bicarbonate loading did not alter blood [Na+] (F2.0, 20.0 = 1.0, P = 0.394, η
2 = 0.02, Fig. 3c), 289 
although there were significant increases shown post-exercise (F2.0, 20.0 = 20.5, P < 0.0005, η
2 = 0.42). 290 
No condition × time interaction was shown for blood [Na+] (F4.0, 40.0 = 0.3, P = 0.850, η
2 = 0.01). 291 
Similarly, NaHCO3 ingestion did not alter blood [K
+] (F2.0, 20.0 = 0.2, P = 0.848, η
2 = 0.01, Fig. 3d) 292 
despite significant increases post-exercise (F2.0, 20.0 = 41.1, P < 0.0005, η
2 = 0.48), with no condition × 293 
time interaction (F4.0, 40.0 = 0.6, P = 0.660, η
2 = 0.01). 294 
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 295 
Fig. 4 Mean ± SD (a) blood [La–] and (b) heart rate response during the 4 km TT following the ingestion 296 
of 0.3 g·kg–1 body mass NaHCO3 in gelatin or enteric-coated capsules, or a placebo. 
✱Significant 297 
difference between gelatin NaHCO3 and placebo (P < 0.05) 298 
 299 
Physiological and perceptual responses 300 
Blood [La–] was significantly greater (F2.0, 20 = 7.7, P = 0.003, η
2 = 0.03; Fig. 4a) in the gelatin trial 301 
compared with the placebo (mean difference = 2.4 mmol∙L–1, P = 0.003, 95% CI [0.9, 3.8 s], g = 0.9). 302 
No further differences in lactate responses were shown between conditions (P > 0.05), although blood 303 
[La–] progressively increased during all TTs (F1.4, 13.9 = 127.3, P < 0.0005, η
2 = 0.82), without a condition 304 
× time interaction (F2.5, 25.2 = 2.0, P = 0.152, η
2 = 0.01). Heart rate progressively increased throughout 305 
the 4 km TT (F1.1, 10.9 = 43.8, P < 0.0005, η
2 = 0.60; Fig. 4b), although no significant differences were 306 
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shown between conditions (F2.0, 20 = 0.7, P = 0.491, η
2 = 0.01), nor was there a significant condition × 307 
time interaction (F2.3, 22.5 = 1.0, P = 0.385, η
2 = 0.01). Despite improvements in TT performance in both 308 
NaHCO3 conditions, there were no differences in neither RPE (F2.0, 20.0 = 2.2, P = 0.137, η
2 = 0.04), 309 
RPE-L (F2.0, 20.0 = 0.2, P = 0.841, η
2 = 0.01) nor ROF (F2.0, 20.0 = 3.5, P = 0.05, η
2 = 0.03) between 310 
conditions, although there were significant increases in RPE (F3.0, 30.0 = 63.2, P < 0.0005, η
2 = 0.56), 311 
RPE-L (F1.4, 14.4 = 45.2, P < 0.0005, η
2 = 0.53) and ROF (F1.2, 12.4 = 2.2, P < 0.0005, η
2 = 0.67) during 312 
the TT (Table 1). No significant condition × time interactions were revealed for neither RPE (F6.0, 60.0 = 313 
0.9, P = 0.524, η2 = 0.01), RPE-L (F6.0, 60.0 = 0.4, P = 0.893, η
2 = 0.01) nor ROF (F6.0, 60.0 = 0.8, P = 314 
0.583, η2 = 0.01). 315 
 316 
Table 1. Mean ± SD perceptual responses during the 4 km TT. 317 
 Condition 
 Placebo Gelatin Enteric 
RPE (AU) 
 1-km 11.6 ± 1.9 11.5 ± 2.8 12.5 ± 2.0 
 2-km 13.3 ± 2.2 12.4 ± 2.5  14.0 ± 1.7* 
 3-km 14.8 ± 2.2* 13.8 ± 1.8 15.2 ± 2.1* 
 4 km 16.6 ± 2.3* 16.0 ± 2.8* 16.6 ± 2.2* 
RPE-L (AU) 
 1-km 13.5 ± 2.7 13.6 ± 2.2 13.7 ± 2.1 
 2-km 14.7 ± 2.5 14.6 ± 2.2* 15.0 ± 1.7 
 3-km 16.1 ± 1.9* 15.9 ± 2.0* 16.2 ± 1.6* 
 4 km 17.3 ± 2.4 17.8 ± 1.7* 18.0 ± 2.1* 
ROF (AU) 
 1-km 3.9 ± 1.8 3.2 ± 1.3 3.5 ± 1.1 
 2-km 5.0 ± 1.4* 4.7 ± 0.9* 5.2 ± 1.0* 
 3-km 5.8 ± 1.1* 5.4 ± 1.2 6.2 ± 1.3 
 4 km 7.5 ± 1.3* 6.6 ± 1.2* 7.5 ± 1.4* 
*Denotes a significant difference from the previous timepoint (P < 
0.05). 
 318 
Gastrointestinal symptoms 319 
No GI symptoms were reported pre-ingestion in all conditions. No participants reported GI symptoms 320 
pre-exercise with the placebo, whereas fewer participants experienced symptoms with enteric-coated 321 
(n = 7) compared to gelatin (n = 3) NaHCO3. Pre-exercise GI symptom scores were significantly higher 322 
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following gelatin NaHCO3 (3.6 ± 3.9 AU) compared with placebo (P = 0.043), with no difference 323 
between enteric-coated NaHCO3 (1.0 ± 1.7 AU) and placebo (P = 0.324). Furthermore, pre-exercise GI 324 
symptoms were less severe with enteric-coated NaHCO3 compared to gelatin at the individual level 325 
(Table 2), although group symptom scores were similar (P = 0.211) between enteric-coated and gelatin 326 
capsules (mean difference = 2.6 AU, P = 0.211, 95% CI [1.1, 6.2 AU]). 327 
 328 
Table 2. Individual GI symptom scores immediately before exercise. Symptoms are displayed in bold 329 
for clarity and scores are displayed in parentheses. 330 
 Condition 
 Placebo Gelatin Enteric 
Participant    
1 No symptom (0.0) No symptom (0.0) No symptom (0.0) 
2 No symptom (0.0) Diarrhoea (10.0) No symptom (0.0) 
3 No symptom (0.0) Stomach ache (1.3) No symptom (0.0) 
4 No symptom (0.0) Stomach cramp (1.5) No symptom (0.0) 
5 No symptom (0.0) No symptom (0.0) Flatulence (5.0) 
6 No symptom (0.0) Diarrhoea (6.0) No symptom (0.0) 
7 No symptom (0.0) Bloating (5.0) Bloating (3.0) 
8 No symptom (0.0) No symptom (0.0) No symptom (0.0) 
9 No symptom (0.0) Bowel urgency (5.0) No symptom (0.0) 
10 No symptom (0.0) Diarrhoea (10.0) Bloating (2.0) 
11 No symptom (0.0) No symptom (0.0) No symptom (0.0) 
 331 
Discussion 332 
This is the first study to investigate the effect of enteric-coated NaHCO3 supplementation on exercise 333 
performance, specifically that which would typically benefit from extracellular buffering agents. The 334 
main finding of this study was that ingesting enteric-coated NaHCO3 prior to exercise improved (~ 335 
2.3%) subsequent 4 km cycling TT performance among trained cyclists. Despite inducing a lower 336 
degree of metabolic alkalosis with enteric-coated NaHCO3 (Fig. 3), there were no differences in exercise 337 
performance compared with a standard ingestion form (i.e. gelatin capsules). Furthermore, enteric-338 
coated NaHCO3 reduced GI symptoms experienced immediately before exercise compared with gelatin 339 
capsules (Table 2), although subjective ratings of GI symptoms in this sample were low. When taken 340 
together, these data suggest that enteric-coated NaHCO3 improves high-intensity cycling performance 341 
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in those with mild to moderate GI symptoms. However, the effects of enteric-coated NaHCO3 on 342 
exercise performance could be greater in those who experience more severe GI symptoms at the onset 343 
of exercise, although this warrants further investigation. Enteric-coated NaHCO3 supplementation may 344 
therefore offer an alternate strategy to improve high-intensity exercise performance and mitigate GI 345 
symptoms associated with acute bicarbonate loading. 346 
Numerous studies have investigated the effects of NaHCO3 on simulated high-intensity TT 347 
events with equivocal outcomes (Callahan et al. 2017; Gough et al. 2018). Where some studies have 348 
reported performance improvements (Gough et al. 2018), others have reported no benefit (Callahan et 349 
al. 2017; Correia-Oliveira et al. 2017) following supplementation. This disparity between studies could 350 
be explained by the timing of supplementation, given that the current study demonstrated positive 351 
outcomes when exercise was timed with peak alkalosis. Studies that have reported no effect of NaHCO3 352 
ingestion during similar exercise protocols have administered the supplement at a standardised time 353 
(Callahan et al. 2017; Correia-Oliveira et al. 2017) despite considerable variability in the time taken to 354 
reach metabolic alkalosis (Jones et al. 2016). Time between ingestion and the onset of exercise largely 355 
determines the degree of metabolic alkalosis in terms of blood [HCO3
–] and pH (Heibel et al. 2018), 356 
which in turn, may influence the ergogenicity of NaHCO3 supplementation (Carr et al. 2011a). 357 
Interestingly, the effect of NaHCO3 on exercise performance in the present study was mediated by the 358 
ingestion form, with a small to moderate effect on performance time (2.3–2.6%) with enteric-coated 359 
and gelatin NaHCO3, respectively. The present study reported a mean 5.6 mmol∙L
–1 increase in blood 360 
[HCO3
–] with gelatin compared to placebo, which is lower than the 3.8 mmol∙L–1 increase shown with 361 
the enteric-coated capsules. This finding is consistent with previous studies that have investigated the 362 
acid-base kinetics following NaHCO3 ingestion (Hilton 2019b), which could account for the difference 363 
in effect size reported in the present study. Nevertheless, exercise performance still improved with 364 
enteric-coated NaHCO3 supplementation, which questions the 5-6 mmol∙L
–1 threshold suggested to 365 
improve performance (Carr et al. 2011a; Heibel et al. 2018). Furthermore, the improvements in 4 km 366 
cycling TT performance in the present study are similar to previous studies, despite higher pre-exercise 367 
blood [HCO3
–] reported by others (Gough et al. 2018). Given this disparity between studies, it is 368 
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unlikely that timing is the only factor modulating the ergogenicity of NaHCO3 during high-intensity 369 
exercise. 370 
Whilst an individualised ingestion strategy may increase the likelihood of commencing exercise 371 
with greater blood buffering capacity, it is not clear whether this optimises the ergogenicity of NaHCO3 372 
supplementation. Individualising the timing of supplementation may also not be practical at present, for 373 
some athletes, given that this requires access to a blood-gas analyser. In the current study however, 374 
mean ingestion timings corresponded to those that have been previously suggested with enteric-coated 375 
NaHCO3 (Hilton et al. 2019b). Furthermore, it is important to note that enteric-coated capsules delay 376 
the time-to-reach peak blood [HCO3
–] following NaHCO3 ingestion, suggesting that current 377 
recommendations (e.g. 60-90 min before exercise) are not appropriate for this ingestion form. Instead, 378 
the current study adds to the growing body of evidence suggesting that enteric-coated NaHCO3 should 379 
be ingested ~ 120 min prior to exercise to maximise blood [HCO3
–] if a standardised ingestion timing 380 
strategy is adopted (Hilton et al. 2019b). Whilst participants ingested the capsules in a fasted state in 381 
the present study, co-ingestion with food may delay gastric emptying and alter the release of NaHCO3 382 
(Davis et al. 1986). Further research should look to compare the effects of an individualised and 383 
standardised ingestion time on subsequent performance, including the effects of prandial state on acid-384 
base responses and GI symptoms following NaHCO3 ingestion. 385 
Given that enteric-coated NaHCO3 improves exercise performance among those with mild to 386 
moderate GI symptoms, the effects on exercise performance may be enhanced among those with more 387 
severe GI symptoms at the onset of exercise. While GI distress was significantly reduced in some 388 
individuals in the current study (Table 2), numerous individuals did not report symptoms at the onset 389 
of exercise. Although ergogenic doses (~ 0.3 g∙kg–1 body mass) of NaHCO3 may induce GI symptoms, 390 
these may not necessarily be timed with exercise performance. This is consistent with previous studies 391 
(Hilton et al. 2019a; Hilton et al. 2019b) demonstrating the reduced incidence of GI symptoms at the 392 
time of peak alkalosis, despite severe symptoms at other timepoints. It is therefore difficult to elucidate 393 
whether GI symptoms can negate the ergogenic effects of NaHCO3 supplementation from the current 394 
data, since the overall incidence and severity of GI symptoms was low. Nevertheless, GI symptoms 395 
may hinder high-intensity exercise performance or dampen the ergogenic effects of NaHCO3 396 
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supplementation (Saunders et al. 2014). Further research should therefore examine the effects of 397 
enteric-coated NaHCO3 supplementation in those who typically report moderate to severe GI symptoms 398 
at the onset of exercise, as the effects may be greater among these individuals. Given that only few 399 
participants reported GI symptoms following enteric-coated NaHCO3 supplementation, future studies 400 
could consider increasing the dose (> 0.3 g·kg–1 body mass), which may also increase blood [HCO3
–]. 401 
Whilst psychological indicators of perceived exertion and fatigue increased during exercise, no 402 
differences were reported between the placebo and NaHCO3 conditions (Table 1), suggesting an 403 
alternative mechanism other than reductions in afferent feedback to the central nervous system (Siegler 404 
& Marshall, 2015). Nevertheless, this finding indicates the enhancements in power output were attained 405 
at a relatively similar RPE when supplementing with NaHCO3. Similarly, despite distinct changes in 406 
blood [Na+] and [K+] during exercise, no differences were shown between NaHCO3 and placebo (Fig. 407 
3). Changes in these strong ions can impair muscle excitability (Cairns & Lindinger, 2008), therefore 408 
suggesting that improvements in performance were not due to ionic shifts in [Na+] and [K+] associated 409 
with enhanced contractility. Nevertheless, enhanced muscle contractile function cannot be dismissed as 410 
a potential mechanism, as altered calcium handling can improve mechanical efficiency (Siegler et al. 411 
2016), although this cannot be elucidated from the current study. Alternatively, given that pre-exercise 412 
blood [HCO3
–] and pH were greater in the NaHCO3 conditions compared to placebo, the performance 413 
improvements shown in the current study may be attributed to increases in extracellular buffering 414 
capacity. Reinforced extracellular concentrations of bicarbonate are suggested to promote H+ efflux 415 
from intramuscular to extracellular regions through increases in monocarboxylate transporter activity, 416 
which maintains muscle pH during exercise (Bishop et al. 2006). Given the delayed onset of 417 
intramuscular acidosis, NaHCO3 promotes glycolytic enzyme activity and flux, as indicated through 418 
increases in muscle glycogen utilisation and lactate concentrations (Hollidge-Horvat et al. 2000; Siegler 419 
et al. 2016). Although muscle pH and lactate were not measured in the current study, increases in muscle 420 
pH and lactate efflux have been shown during exercise following NaHCO3 supplementation (Costill et 421 
al. 1984). Augmenting glycolytic flux may have therefore permitted exercise at higher intensities and 422 
could explain the performance improvements reported in the current study. This would account for the 423 
greater blood [La–] shown with gelatin NaHCO3, although the increases reported with enteric-coated 424 
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capsules did not reach significance (Fig. 4a). Given that monocarboxylate transporters 1- and 4 are 425 
stimulated by the intra- to extracellular [H+] gradient, the greater extracellular pH shown with gelatin 426 
capsules may have upregulated the co-transport of H+ and lactate to a greater extent and could account 427 
for differences in the ergogenic effect size (0.3%). This may also explain why power output was greater 428 
when NaHCO3 was given in gelatin capsules (Fig. 2), although this did not result in greater overall 429 
performance times compared to enteric-coated capsules. Therefore, the current evidence suggests that 430 
while pre-exercise blood [HCO3
–] does not determine the overall ergogenicity of NaHCO3 431 
supplementation, the magnitude of such effects may be increased by a greater degree of metabolic 432 
alkalosis. 433 
In summary, this study is the first to demonstrate that 0.3 g∙kg–1 body mass of enteric-coated 434 
NaHCO3 improves high-intensity exercise performance when timed with peak alkalosis. This study also 435 
provides novel data highlighting that ingestion form (e.g gelatin or enteric-coated capsules) can mediate 436 
the effects on exercise performance, potentially through the degree of induced alkalosis. In order to 437 
understand the implications of GI symptoms on exercise performance, further research should compare 438 
the effects of enteric-coated NaHCO3 supplementation on exercise performance in those who 439 
experience severe symptoms immediately before exercise, particularly as GI distress may be ergolytic 440 
among these individuals. Furthermore, given the growing range of ingestion forms commercially 441 
available to athletes (e.g. liquid, gelatin capsules, enteric-coated capsules), future studies should 442 
compare the effects on exercise performance. Nonetheless, acute enteric-coated NaHCO3 consumption 443 
improves 4 km cycling TT performance and therefore, may offer an appropriate ergogenic strategy for 444 
those who experience GI side-effects following supplementation. 445 
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